Late-Onset Immunotherapy-Induced Myocarditis 2 Years After Checkpoint Inhibitor Initiation

Andrew T Nguyen; Gerald J Berry; Ronald M Witteles; Dung T Le; Sean M Wu; George A Fisher; Han Zhu

doi:10.1016/j.jaccao.2022.04.007

Late-Onset Immunotherapy-Induced Myocarditis 2 Years After Checkpoint Inhibitor Initiation

JACC CardioOncol. 2022 Dec 20;4(5):727-730. doi: 10.1016/j.jaccao.2022.04.007. eCollection 2022 Dec.

Authors

Andrew T Nguyen¹, Gerald J Berry², Ronald M Witteles^{1

3}, Dung T Le⁴, Sean M Wu^{1

3}, George A Fisher^{1

5}, Han Zhu^{1

2}

Affiliations

¹ Department of Medicine, Stanford University, Stanford, California, USA.
² Department of Pathology, Stanford University, Stanford, California, USA.
³ Division of Cardiovascular Medicine, Stanford University School of Medicine, Stanford, California, USA.
⁴ Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, Maryland, USA.
⁵ Division of Medical Oncology, Stanford University, Stanford, California, USA.

No abstract available

Keywords: ICI, immune checkpoint inhibitor; PD-1, programmed cell death receptor-1; cardiomyopathy; colorectal cancer; diagnosis; immunotherapy; irAE, immune-related adverse event; myocarditis; treatment.

Publication types

Review

Grants and funding

K08 HL161405/HL/NHLBI NIH HHS/United States